Metolazone
Metolazone (metolazone) is a small molecule pharmaceutical. Metolazone was first approved as Diulo on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA. The pharmaceutical is active against solute carrier family 12 member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Metolazone (discontinued: Diulo, Metolazone, Mykrox, Zaroxolyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metolazone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MYKROX | Chartwell Pharmaceuticals | N-019532 DISCN | 1987-10-30 | 1 products |
| DIULO | G.D. Searle | N-018535 DISCN | 1982-01-01 | 3 products |
| ZAROXOLYN | i3 Pharmaceuticals | N-017386 DISCN | 1982-01-01 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| metolazone | ANDA | 2024-12-24 |
| mykrox tablets | 2006-01-12 | |
| zaroxolyn | New Drug Application | 2016-08-06 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA08: Metolazone
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA12: Metolazone and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 2 | 4 | 12 | 6 | 25 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 2 | 3 |
| Acute liver failure | D017114 | HP_0004448 | — | — | — | — | 2 | 1 | 3 |
| Covid-19 | D000086382 | — | — | — | — | — | 1 | 1 | 2 |
| Iron overload | D019190 | — | — | — | 1 | — | 1 | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Edema | D004487 | HP_0000969 | R60.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Hypernatremia | D006955 | HP_0003228 | E87.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metolazone |
| INN | metolazone |
| Description | Metolazone is a quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. It has a role as a diuretic, an antihypertensive agent and an ion transport inhibitor. It is a member of quinazolines, an organochlorine compound and a sulfonamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C |
Identifiers
| PDB | — |
| CAS-ID | 17560-51-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL878 |
| ChEBI ID | 64354 |
| PubChem CID | 4170 |
| DrugBank | DB00524 |
| UNII ID | TZ7V40X7VX (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A3
SLC12A3
Organism
Homo sapiens
Gene name
SLC12A3
Gene synonyms
NCC, TSC
NCBI Gene ID
Protein name
solute carrier family 12 member 3
Protein synonyms
Na-Cl cotransporter, Na-Cl symporter, NaCl electroneutral thiazide-sensitive cotransporter, NCC, sodium-chloride co-transporter, solute carrier family 12 (sodium/chloride transporter), member 3, thiazide-sensitive Na-Cl cotransporter, Thiazide-sensitive sodium-chloride cotransporter
Uniprot ID
Mouse ortholog
Slc12a3 (20497)
solute carrier family 12 member 3 (P59158)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Metolazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,259 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,268 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use